With a projected compound annual growth rate (CAGR) near 8% between 2017 and 2021 in the botanical and plant-derived drugs market, pharmaceutical companies can no longer ignore the high-yield potential found within this explosive industry.
Why the Botanical Pharmaceuticals Market Is Growing Rapidly
Download Whitepaper: Cannabis Botanical Products: Science, Regulation, and Quality Management
Expanding Government Support for Botanical Drug Production
Since the FDA declared botanical drugs officially legal in 2004, many government initiatives have followed. The government sees the growing demand and need within the market and has answered with a friendlier regulator environment for botanical drugs and a greater number of awarded contracts to large pharma companies.
Rising Demand for Naturally Derived Treatment Options
The increase in natural and holistic health treatment has long been on the uprise, however, both the traditional medical world and the holistic health camp have struggled to find a common ground. Consumer demand has now forced many companies to do just that. And the results are benefitting everyone.
Improved Production Efficiency and Lower Development Costs
Advancements in agricultural technology, extraction methods, and laboratory processing have significantly improved the efficiency of botanical drug production. These improvements have helped reduce development costs while increasing scalability and consistency in plant-based pharmaceutical manufacturing.
As a result, botanical drug development is becoming more economically viable for both large pharmaceutical companies and emerging biotech firms.
Expansion of Global Supply and Exchange Networks
International markets such as China, India, and other regions with strong botanical resources are becoming increasingly open to the exchange of plant-based materials and raw compounds used in pharmaceutical production.
This global integration is strengthening supply chains and improving access to diverse botanical sources, further supporting market growth and innovation.
Increasing Pressure on Traditional Pharmaceutical Development
Traditional drug development continues to face rising regulatory complexity, longer development timelines, and higher production costs. These challenges have slowed innovation in some areas of conventional pharmaceuticals, creating space for alternative approaches such as botanical drug development.
In contrast, plant-based compounds often offer more flexible pathways for research, development, and regulatory approval.
Market Outlook: Strong Growth Ahead
Collectively, these factors are creating a highly favorable environment for the continued expansion of botanical pharmaceuticals. Increased regulatory clarity, rising consumer demand, improved production efficiency, and global supply chain integration are all contributing to sustained market growth.
Organizations that position themselves early in this evolving landscape will be better prepared to take advantage of emerging opportunities in botanical drug research and manufacturing.
Supporting Botanical Drug Development with Proper Laboratory Equipment
To fully capitalize on this market expansion, laboratories must be equipped with systems designed to ensure safety, contamination control, and regulatory compliance throughout the botanical research and manufacturing process.
Air Science offers a range of solutions designed to support these environments, including:
- Purair® Basic and Advanced Ductless Fume Hoods – for safe handling of chemical vapors and volatile compounds
- Purair BIO Biological Safety Cabinets – for contamination control in sensitive biological workflows
- Purair FLEX Enclosures – for flexible, application-specific laboratory protection
These systems help botanical and cannabis manufacturers maintain controlled environments that support safe, efficient, and compliant product development.